Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.…
Atara Biotherapeutics: Q3 Earnings Snapshot
Atara Biotherapeutics (NASDAQ: ATRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 6.330 USD on 20 November 2026, down 46.4% over 52 weeks. Its 52-week range is 3.920 USD to 19.14 USD: the price is 66.9% below the high and 61.5% above the low.
Its market capitalisation is 64.49M USD.
Atara Biotherapeutics reports return on equity of -84.9%, an operating margin of -267.6% and revenue down 64.6% year over year.
It holds more cash than debt, a net cash position of 351.00K USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 13.67 USD is 115.9% above the current price. The next earnings report is expected on 16 March 2027.